Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have earned an average recommendation of “Buy” from the ten research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $16.2222.

A number of research analysts recently weighed in on IVA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. HC Wainwright set a $24.00 target price on Inventiva and gave the company a “buy” rating in a research report on Wednesday, January 28th. Leerink Partners initiated coverage on Inventiva in a research report on Monday, January 12th. They set an “outperform” rating and a $12.00 price target for the company. UBS Group initiated coverage on Inventiva in a research note on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Barclays started coverage on shares of Inventiva in a research note on Tuesday, January 27th. They set an “overweight” rating and a $18.00 target price on the stock.

Inventiva Stock Down 1.5%

IVA opened at $6.08 on Wednesday. The firm’s fifty day simple moving average is $5.48 and its two-hundred day simple moving average is $5.06. Inventiva has a 52-week low of $2.52 and a 52-week high of $7.98.

Institutional Trading of Inventiva

Several large investors have recently bought and sold shares of the business. Franklin Resources Inc. acquired a new position in Inventiva in the fourth quarter valued at approximately $11,626,000. Goldman Sachs Group Inc. purchased a new stake in Inventiva in the fourth quarter valued at $1,998,000. NewEdge Advisors LLC purchased a new stake in Inventiva in the third quarter valued at $116,000. Millennium Management LLC purchased a new position in shares of Inventiva during the 3rd quarter worth $649,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Inventiva during the 4th quarter worth about $603,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.